Drug intelligence / Profile preview

SP-3204

Development stage: Preclinical
Lead developer: Salarius Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

SP-3204 is a novel molecular glue degrader developed by Salarius Pharmaceuticals. It functions as a targeted protein degrader that induces the selective degradation of GSPT1 (G1 to S phase transition 1), a protein implicated in the proliferation of cancer cells. By promoting the ubiquitination and subsequent proteasomal degradation of GSPT1, SP-3204 aims to inhibit tumor growth in neoplasms. The drug is currently in preclinical development and represents an innovative approach within the field of targeted protein degradation for oncology[1][3][8].

Targets

CRBN (Cereblon)GSPT1 (G1 to S phase transition 1)

Beyond the preview

Go deeper on SP-3204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-3204.

Explore the full profile